Scientists probe hidden link between lung disease and mental health
NCT ID NCT07291167
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 300 adults with bronchiectasis, a chronic lung condition, to understand why many also experience anxiety and depression. Researchers will collect blood, sputum, and stool samples to analyze metabolic pathways and identify biomarkers. The goal is to find clues that could improve treatment and reduce disease flare-ups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with all-cause bronchiectasis would be included, such as those with tuberculosis history and genetic disorders.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years * Participants' pulmonary imaging findings and clinical presentation met the diagnostic criteria for bronchiectasis * Clinically stable (no antibiotics or oral corticosteroids within 4 weeks prior to enrolment); * Patients who are willing to sign the consent form and participate in the study. Exclusion Criteria: * Age \<18 years * Does not meet the diagnostic criteria for bronchiectasis * Participants with cystic fibrosis or previous lung transplantation * Participants who are unable to cooperate with the study due to dysfunction of vital systems such as heart, brain, liver, and kidneys, or who are unable to participate in the study due to comorbid serious diseases * Participants with active disorders, including active tuberculosis, active allergic bronchopulmonary aspergillosis, active nontuberculous mycobacterial infection and malignancy or secondary traction bronchiectasis associated with pulmonary fibrosis * Pregnant or lactating females * Who are not able to provide informed consent or who refuse to participate in the clinical study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bronchiectasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Wuhan Union Hospital,China
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simpler antibiotic course clear lung infections as well as a stronger one?
- A new twist on lung rehab: helping the helpers
- Gum treatment may lower lung flare-ups in bronchiectasis patients
- Can a daily pill cut dangerous lung Flare-Ups in bronchiectasis?
- Lung inflammation may speed heart aging, study investigates
- Scientists track hidden threat of antibiotic resistance in lung patients